Lucia Malisova, Iveta Vrbova, Katarina Pomorska, Vladislav Jakubu, Helena Zemlickova
{"title":"头孢iderocol对碳青霉烯耐药肠杆菌和铜绿假单胞菌的体外活性。","authors":"Lucia Malisova, Iveta Vrbova, Katarina Pomorska, Vladislav Jakubu, Helena Zemlickova","doi":"10.1089/mdr.2023.0090","DOIUrl":null,"url":null,"abstract":"<p><p>The objective of this study was to assess the susceptibility of cefiderocol against multidrug-resistant carbapenemase-producing and nonproducing bacteria. The panel comprised 182 isolates of the order <i>Enterobacterales</i>, and 40 strains of <i>Pseudomonas aeruginosa</i>. Antimicrobial susceptibility testing has been performed using broth microdilution method according to the European Committee on Antimicrobial Susceptibility Testing recommendations. Mass spectrometry matrix-assisted laser desorption/ionization-time of flight mass spectrometry and carbapenemase-producing test were used to verify the presence of carbapenemases in clinical isolates. The genetic expression of single carbapenemases (<i>bla</i><sub>KPC</sub>, <i>bla</i><sub>OXA-48</sub>, <i>bla</i><sub>NDM</sub>, <i>bla</i><sub>VIM</sub>, <i>bla</i><sub>IMP</sub>, <i>bla</i><sub>GES</sub>) was determined by real-time polymerase chain reaction. Cefiderocol exhibited a good activity against the majority of strains tested in this study. Altogether, growth of 81.9% (<i>n</i> = 149) strains of the order <i>Enterobacterales</i> and 77.5% (<i>n</i> = 31) of <i>P. aeruginosa</i> isolates were inhibited at minimal inhibitory concentration (MIC) ≤2 mg/L. Values MIC<sub>50</sub>/MIC<sub>90</sub> were 0.5/8 mg/L for enterobacteria, and 1/8 mg/L for <i>P. aeruginosa</i>. One isolate (<i>Klebsiella pneumoniae</i>) harboring two carbapenemases (<i>bla</i><sub>OXA-48</sub>, <i>bla</i><sub>NDM</sub>) had cefiderocol MIC 0.5 mg/L. In enterobacteria resistant to cefiderocol, <i>bla</i><sub>NDM</sub> carbapenemase prevailed (43.3%, <i>n</i> = 29), followed by <i>bla</i><sub>OXA-48</sub> (31.3%, <i>n</i> = 21) and <i>bla</i><sub>KPC</sub> (4.5%, <i>n</i> = 3). <i>bla</i><sub>IMP</sub> (<i>n</i> = 8) and <i>bl</i>a<sub>VIM</sub> (<i>n</i> = 1) metallo-β-lactamases dominated in cefiderocol-resistant <i>P. aeruginosa</i> (<i>n</i> = 9) isolates. Very good susceptibility (100%) to this drug showed <i>bla</i><sub>GES</sub>-positive strains of <i>P. aeruginosa</i> (<i>n</i> = 8) and isolates resistant to meropenem without confirmed carbapenemase gene (<i>n</i> = 10). In this study, cefiderocol demonstrated potent activity against important nosocomial pathogens, therefore, therapeutic options of this drug against multidrug-resistant bacteria should be considered.</p>","PeriodicalId":18701,"journal":{"name":"Microbial drug resistance","volume":" ","pages":"485-491"},"PeriodicalIF":2.3000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611972/pdf/","citationCount":"0","resultStr":"{\"title\":\"<i>In Vitro</i> Activity of Cefiderocol Against Carbapenem-Resistant <i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i>.\",\"authors\":\"Lucia Malisova, Iveta Vrbova, Katarina Pomorska, Vladislav Jakubu, Helena Zemlickova\",\"doi\":\"10.1089/mdr.2023.0090\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The objective of this study was to assess the susceptibility of cefiderocol against multidrug-resistant carbapenemase-producing and nonproducing bacteria. The panel comprised 182 isolates of the order <i>Enterobacterales</i>, and 40 strains of <i>Pseudomonas aeruginosa</i>. Antimicrobial susceptibility testing has been performed using broth microdilution method according to the European Committee on Antimicrobial Susceptibility Testing recommendations. Mass spectrometry matrix-assisted laser desorption/ionization-time of flight mass spectrometry and carbapenemase-producing test were used to verify the presence of carbapenemases in clinical isolates. The genetic expression of single carbapenemases (<i>bla</i><sub>KPC</sub>, <i>bla</i><sub>OXA-48</sub>, <i>bla</i><sub>NDM</sub>, <i>bla</i><sub>VIM</sub>, <i>bla</i><sub>IMP</sub>, <i>bla</i><sub>GES</sub>) was determined by real-time polymerase chain reaction. Cefiderocol exhibited a good activity against the majority of strains tested in this study. Altogether, growth of 81.9% (<i>n</i> = 149) strains of the order <i>Enterobacterales</i> and 77.5% (<i>n</i> = 31) of <i>P. aeruginosa</i> isolates were inhibited at minimal inhibitory concentration (MIC) ≤2 mg/L. Values MIC<sub>50</sub>/MIC<sub>90</sub> were 0.5/8 mg/L for enterobacteria, and 1/8 mg/L for <i>P. aeruginosa</i>. One isolate (<i>Klebsiella pneumoniae</i>) harboring two carbapenemases (<i>bla</i><sub>OXA-48</sub>, <i>bla</i><sub>NDM</sub>) had cefiderocol MIC 0.5 mg/L. In enterobacteria resistant to cefiderocol, <i>bla</i><sub>NDM</sub> carbapenemase prevailed (43.3%, <i>n</i> = 29), followed by <i>bla</i><sub>OXA-48</sub> (31.3%, <i>n</i> = 21) and <i>bla</i><sub>KPC</sub> (4.5%, <i>n</i> = 3). <i>bla</i><sub>IMP</sub> (<i>n</i> = 8) and <i>bl</i>a<sub>VIM</sub> (<i>n</i> = 1) metallo-β-lactamases dominated in cefiderocol-resistant <i>P. aeruginosa</i> (<i>n</i> = 9) isolates. Very good susceptibility (100%) to this drug showed <i>bla</i><sub>GES</sub>-positive strains of <i>P. aeruginosa</i> (<i>n</i> = 8) and isolates resistant to meropenem without confirmed carbapenemase gene (<i>n</i> = 10). In this study, cefiderocol demonstrated potent activity against important nosocomial pathogens, therefore, therapeutic options of this drug against multidrug-resistant bacteria should be considered.</p>\",\"PeriodicalId\":18701,\"journal\":{\"name\":\"Microbial drug resistance\",\"volume\":\" \",\"pages\":\"485-491\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2023-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611972/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Microbial drug resistance\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/mdr.2023.0090\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/8/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Microbial drug resistance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/mdr.2023.0090","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
In Vitro Activity of Cefiderocol Against Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa.
The objective of this study was to assess the susceptibility of cefiderocol against multidrug-resistant carbapenemase-producing and nonproducing bacteria. The panel comprised 182 isolates of the order Enterobacterales, and 40 strains of Pseudomonas aeruginosa. Antimicrobial susceptibility testing has been performed using broth microdilution method according to the European Committee on Antimicrobial Susceptibility Testing recommendations. Mass spectrometry matrix-assisted laser desorption/ionization-time of flight mass spectrometry and carbapenemase-producing test were used to verify the presence of carbapenemases in clinical isolates. The genetic expression of single carbapenemases (blaKPC, blaOXA-48, blaNDM, blaVIM, blaIMP, blaGES) was determined by real-time polymerase chain reaction. Cefiderocol exhibited a good activity against the majority of strains tested in this study. Altogether, growth of 81.9% (n = 149) strains of the order Enterobacterales and 77.5% (n = 31) of P. aeruginosa isolates were inhibited at minimal inhibitory concentration (MIC) ≤2 mg/L. Values MIC50/MIC90 were 0.5/8 mg/L for enterobacteria, and 1/8 mg/L for P. aeruginosa. One isolate (Klebsiella pneumoniae) harboring two carbapenemases (blaOXA-48, blaNDM) had cefiderocol MIC 0.5 mg/L. In enterobacteria resistant to cefiderocol, blaNDM carbapenemase prevailed (43.3%, n = 29), followed by blaOXA-48 (31.3%, n = 21) and blaKPC (4.5%, n = 3). blaIMP (n = 8) and blaVIM (n = 1) metallo-β-lactamases dominated in cefiderocol-resistant P. aeruginosa (n = 9) isolates. Very good susceptibility (100%) to this drug showed blaGES-positive strains of P. aeruginosa (n = 8) and isolates resistant to meropenem without confirmed carbapenemase gene (n = 10). In this study, cefiderocol demonstrated potent activity against important nosocomial pathogens, therefore, therapeutic options of this drug against multidrug-resistant bacteria should be considered.
期刊介绍：
Microbial Drug Resistance (MDR) is an international, peer-reviewed journal that covers the global spread and threat of multi-drug resistant clones of major pathogens that are widely documented in hospitals and the scientific community. The Journal addresses the serious challenges of trying to decipher the molecular mechanisms of drug resistance. MDR provides a multidisciplinary forum for peer-reviewed original publications as well as topical reviews and special reports.
MDR coverage includes:
Molecular biology of resistance mechanisms
Virulence genes and disease
Molecular epidemiology
Drug design
Infection control.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
